TUBERCULOSIS

Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy

P A Jenkins¹, I A Campbell², J Banks³, C M Gelder², R J Prescott⁴, A P Smith²

¹ Mycobacterium Reference Laboratory, Cardiff, UK
² Llandough Hospital, Penarth, UK
³ Singleton Hospital, Swansea, UK
⁴ Department of Medical Statistics, Edinburgh University, Edinburgh, UK

Dr I A Campbell, Llandough Hospital, Penarth CF64 5SD, UK; ian.campbell{at}cardiffandvale.wales.nhs.uk

Background: The mainstays of treatment for pulmonary disease caused by opportunist mycobacteria are rifampicin (R) and ethambutol (E). The role of macrolides, quinolones and immunotherapy with Mycobacterium vaccae is not clear. A trial was undertaken to compare clarithromycin (Clari) and ciprofloxacin (Cipro) as third drugs added after 2 years of treatment with R and E for pulmonary disease caused by M avium-intracellulare (MAC), M malmoense and M xenopi (REClari and RECipro). An optional comparison of immunotherapy with M vaccae vs no immunotherapy was also performed.

Methods: Progress was monitored annually during the 2 years of treatment and for 3 years thereafter. If the patient was not improving at 1 year the regimen was supplemented by the addition of the drug not received in the original allocation of treatment.

Results: 371 patients (186 REClari, 185 RECipro) entered the study (170 MAC, 167 M malmoense, 34 M xenopi). All-cause mortality was high for both groups (44% REClari, 43% RECipro); for MAC it was higher with REClari than with RECipro (48% vs 29%) but for M malmoense (42% vs 56%) and M xenopi (29% vs 47%) it was higher with RECipro (p = 0.006). 3% died from their mycobacterial disease (REClari = RECipro). At the end of treatment, 4% of REClari and 10% of RECipro patients still had positive cultures. Among those with negative cultures at the end of treatment, 6% of the REClari group and 4% of the RECipro group had relapsed. At 5 years 30% of the REClari group were known to have completed treatment as allocated and to be alive and cured compared with 21% of the RECipro group (p = 0.04), but this difference was principally due to those with M malmoense (REClari 38%, RECipro 20%). Patients with MAC or M xenopi were more likely to have a poor outcome than those with M malmoense (p = 0.004), with no difference between REClari and RECipro. Overall, 20% in each group were unable to tolerate the regimen allocated, Cipro being associated with more unwanted effects than Clari (16% vs 9%, p = 0.05). No significant differences in outcomes were found between M vaccae-treated patients and those not treated with M vaccae immunotherapy.

Conclusion: Considering all three species together, there were no differences in outcome between the REClari and RECipro groups. Immunotherapy did not improve outcome. New therapies, optimised management of co-morbid conditions and a more holistic approach must be explored in the hope of improving outcome.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2008 63: 571. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Hoefsloot, W., van Ingen, J., de Lange, W. C. M., Dekhuijzen, P. N. R., Boeree, M. J., van Soolingen, D. (2009). Clinical relevance of Mycobacterium malmoense isolation in the Netherlands. Eur Respir J 34: 926-931 [Abstract] [Full Text]  
• van Ingen, J, Bendien, S A, de Lange, W C M, Hoefsloot, W, Dekhuijzen, P N R, Boeree, M J, van Soolingen, D (2009). Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 64: 502-506 [Abstract] [Full Text]  
• Andrejak, C, Lescure, F-X, Pukenyte, E, Douadi, Y, Yazdanpanah, Y, Laurans, G, Schmit, J-L, Jounieaux, V, and the Xenopi Group, (2009). Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 64: 291-296 [Abstract] [Full Text]